Sugi Predict

Sugi Predict / Compounds / SCHEMBL4458738

SCHEMBL4458738

SCHEMBL4458738

Cc1nc2ncc(Cl)cc2c(=O)o1

nearest known ligand 0.42

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ ELANE P08246 7/20 0.42
▸ HRH4 Q9H3N8 5/20 0.36
▸ HRH3 Q9Y5N1 2/20 0.34
▸ MEN1 O00255 2/20 0.33
▸ KMT2A Q03164 2/20 0.33
▸ HTT P42858 2/20 0.33
▸ HSD17B10 Q99714 2/20 0.33
▸ IDO1 P14902 1/20 0.33
▸ HPGD P15428 1/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ PABPC1 P11940 1/20 0.33
▸ MET P08581 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13185023 0.80 ELANE (0.42) ELANEMEN1KMT2AIDO1KDM4E
SCHEMBL4703500 0.73 IDO1 (0.40) ELANEHRH4MEN1KMT2AHTT
SCHEMBL14833035 0.73 HRH4 (0.34) HRH4HRH3KMT2AIDO1ALDH1A1
SCHEMBL13588387 0.72 ELANE (0.43) ELANEMEN1KMT2AKDM4EALDH1A1
SCHEMBL24658990 0.72 ELANE (0.41) ELANEMEN1KMT2AKDM4EALDH1A1
SCHEMBL28924711 0.71 ELANE (0.56) ELANEMEN1KMT2AKDM4EALDH1A1
SCHEMBL12758394 0.71 ELANE (0.47) ELANEMEN1KMT2AHTTHSD17B10
SCHEMBL31000399 0.71 ELANE (0.70) ELANEMEN1KMT2AHTTKDM4E
SCHEMBL1812732 0.71 ELANE (0.70) ELANEMEN1KMT2AHTTKDM4E
SCHEMBL4558889 0.70 ELANE (0.54) ELANEMEN1KMT2AKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7790739-B2 receptor tyrosine kinase MET inhibitors; anticancer agents; 8-phenyl-10H-furo[2',3':4,5]cyclohepta[1,2-b]pyridin-10-one Merck & Co., Inc. and Merck Sharp & Dohme Corp. (US) 2010-09-07 — — US disclosed
US-20090291941-A1 Tyrosine Kinase Inhibitors MERCK SHARP & DOHME CORP. 2009-11-26 — — US disclosed
US-20090291941-A1 Tyrosine Kinase Inhibitors MERCK SHARP & DOHME CORP. 2009-11-26 — — US disclosed
US-20090291941-A1 Tyrosine Kinase Inhibitors MERCK SHARP & DOHME CORP. 2009-11-26 — — US disclosed
US-20090247565-A1 Tyrosine Kinase Inhibitors MERCK SHARP & DOHME CORP. 2009-10-01 — — US disclosed
US-20090131423-A1 Tyrosine Kinase Inhibitors MERCK & CO., INC. (US) 2009-05-21 — — US disclosed
US-20090131423-A1 Tyrosine Kinase Inhibitors MERCK & CO., INC. (US) 2009-05-21 — — US disclosed
WO-2007050383-A2 TYROSINE KINASE INHIBITORS MERCK & CO., INC. (US) 2007-05-03 — — WO disclosed
WO-2007050401-A2 TYROSINE KINASE INHIBITORS MERCK & CO., INC. (US) 2007-05-03 — — WO disclosed
WO-2007050380-A2 TYROSINE KINASE INHIBITORS MERCK & CO., INC. (US) 2007-05-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090291941-A1 Tyrosine Kinase Inhibitors ABL1, ERBB2, RET ELANE 4328/4885HRH4 2521/4885HRH3 2034/4885
US-20090247565-A1 Tyrosine Kinase Inhibitors ABL1, ERBB2, MET ELANE 4126/4885HRH4 2792/4885HRH3 2313/4885
US-20090131423-A1 Tyrosine Kinase Inhibitors ABL1, ERBB2, MET ELANE 4126/4885HRH4 2792/4885HRH3 2313/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.